TriangleNCT02663518 · OUTCOME
Part 1: Maximum Plasma Concentration (Cmax) of TTI-621
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Nanogram per milliliter
- Interval / dispersion
- Standard Deviation
- Time frame
- Part 1: Pre-dose, end of infusion (EOI), 2, 4, 24, 72, 168 hours post dose on Week 1
Analysis population: Pharmacokinetic (PK)-evaluable set included treated participants with adequate blood sampling to estimate at least one pharmacokinetic PK parameter.
Groups in this outcome
Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg
Participants with advanced relapsed or refractory lymphomas received TTI-621 0.05 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg
Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg
Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg
Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
| Group | Source count |
|---|---|
| Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg | 3 |
| Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg | 3 |
| Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg | 7 |
| Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg | 5 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg | 136.594 | 64.248 | Not reported | Not reported | Not reported |
| Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg | 366.636 | 67.433 | Not reported | Not reported | Not reported |
| Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg | 823.137 | 153.681 | Not reported | Not reported | Not reported |
| Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg | 1579.799 | 518.546 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 64.248
- value
- 136.594
- group Id
- OG001
- spread
- 67.433
- value
- 366.636
- group Id
- OG002
- spread
- 153.681
- value
- 823.137
- group Id
- OG003
- spread
- 518.546
- value
- 1579.799
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 7
- group Id
- OG003
- value
- 5
- units
- Participants
- dispersion Type
- Standard Deviation
- groups
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.05 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG000
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG001
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG002
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg
- description
- Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.
- id
- OG003
- title
- Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg
- param Type
- MEAN
- population Description
- Pharmacokinetic (PK)-evaluable set included treated participants with adequate blood sampling to estimate at least one pharmacokinetic PK parameter.
- reporting Status
- POSTED
- time Frame
- Part 1: Pre-dose, end of infusion (EOI), 2, 4, 24, 72, 168 hours post dose on Week 1
- title
- Part 1: Maximum Plasma Concentration (Cmax) of TTI-621
- type
- SECONDARY
- unit Of Measure
- Nanogram per milliliter
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice